TY - JOUR
KW - Ivermectin
KW - Covid-19
KW - Anti-helminthic
KW - Gynecologic cancers
AU - Mujumdar V
AU - Huang M
AU - Smith LC
AU - Musa F
AB - <h2>Highlights</h2>

<p>•</p>

<p>Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.</p>

<p>•</p>

<p>The data on ivermectin as a gynecologic cancer-fighting compound is lacking.</p>

<p>•</p>

<p>Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.</p>

<p>•</p>

<p>We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.</p>

<p>•</p>

<p>We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.</p>

BT - Gynecologic Oncology Reports
DO - 10.1016/j.gore.2025.101803
LA - eng
M3 - Review Article
N2 - <h2>Highlights</h2>

<p>•</p>

<p>Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.</p>

<p>•</p>

<p>The data on ivermectin as a gynecologic cancer-fighting compound is lacking.</p>

<p>•</p>

<p>Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.</p>

<p>•</p>

<p>We have not assessed ivermectin’s safety and efficacy in gynecologic cancers.</p>

<p>•</p>

<p>We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.</p>

PB - Elsevier BV
PY - 2025
EP - 101803
T2 - Gynecologic Oncology Reports
TI - Ivermectin and gynecologic cancer: What’s the data?
UR - https://pdf.sciencedirectassets.com/311234/1-s2.0-S2352578925X00047/1-s2.0-S2352578925001286/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOj%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJGMEQCIG9G%2B0YitC30FMja3b%2Bij0Zvho9WKM4tnKjTOIcSC1whAiBNYP7b14uy
VL - 60
SN - 2352-5789
ER -